ABD merkezli Johnson&Johnson (J&J), \u00fcretti\u011fi yeni tip koronavir\u00fcs (Kovid-19) a\u015f\u0131s\u0131n\u0131n, klinik deneylerde vir\u00fcse kar\u015f\u0131 g\u00fc\u00e7l\u00fc ba\u011f\u0131\u015f\u0131kl\u0131k olu\u015fturdu\u011funun g\u00f6zlendi\u011fini bildirdi.<\/p>\n
”Ad26.COV2.S” ismi verilen a\u015f\u0131n\u0131n tek dozunun iki doza e\u015fit derecede olumlu reaksiyon verdi\u011fi ve bu nedenle da\u011f\u0131t\u0131m\u0131n\u0131n daha kolay olaca\u011f\u0131 tabir edildi.<\/p>\n
Moderna and Pfizer taraf\u0131ndan yakla\u015f\u0131k 1000 yeti\u015fkin \u00fczerinde klinik deneyleri s\u00fcrd\u00fcr\u00fclen kelam konusu a\u015f\u0131n\u0131n ya\u015fl\u0131 n\u00fcfus \u00fczerindeki tesirinin \u015fu etapta belirli olmad\u0131\u011f\u0131 kaydedildi.<\/p>\n
Klinik deneylerde gen\u00e7 i\u015ftirak\u00e7ilerde ba\u011f\u0131\u015f\u0131kl\u0131k reaksiyonu y\u00fczde 64 civar\u0131nda \u00e7\u0131karken, 65 ya\u015f \u00fcst\u00fcnde bu oran\u0131n y\u00fczde 36 \u00fczere d\u00fc\u015f\u00fck bir d\u00fczeyde kald\u0131\u011f\u0131 belirtildi.<\/p>\n
J&J’nin son evre olarak a\u015f\u0131y\u0131 60 bin ki\u015fi \u00fczerinde deneyece\u011fi, daha sonra ABD Besin ve \u0130la\u00e7 Dairesine kullan\u0131m m\u00fcsaadesi ve seri \u00fcretim i\u00e7in m\u00fcracaat yapaca\u011f\u0131 bildirildi.<\/p>\n
Firma yetkilileri, 3 faz olarak bilinen son etab\u0131n y\u0131l sonuna yahut 2021 ba\u015f\u0131na kadar sonu\u00e7lanmas\u0131n\u0131 beklediklerini, \u00e7al\u0131\u015fmalar tamamland\u0131\u011f\u0131nda a\u015f\u0131n\u0131n g\u00fcvenli\u011fi ve tesirine ait daha fazla ayr\u0131nt\u0131n\u0131n payla\u015f\u0131laca\u011f\u0131n\u0131 a\u00e7\u0131klad\u0131.<\/p>\n
ABD’li ila\u00e7 \u00fcreticisi Johnson&Johnson, 100 milyon dozluk Kovid-19 a\u015f\u0131s\u0131n\u0131n \u00fcretimi ve teslimi i\u00e7in 5 A\u011fustos’ta ABD h\u00fck\u00fcmetiyle 1 milyar dolarl\u0131k mutabakat imzalam\u0131\u015ft\u0131.<\/p>\n
“Ad26.COV2.S” ismi verilen a\u015f\u0131 aday\u0131n\u0131n 1. ve 2. kademe klinik denemelerini ABD ve Bel\u00e7ika’da tamamlayan \u015firket, 3. etab\u0131n da ba\u015far\u0131l\u0131 olmas\u0131 halinde gelecek y\u0131l 1 milyar dozdan fazla a\u015f\u0131n\u0131n tedarik edilmesini hedefliyor.<\/p>\n<\/p>\n
Bloomberg HT<\/span><\/p>\n","protected":false},"excerpt":{"rendered":" ABD merkezli Johnson&Johnson (J&J), \u00fcretti\u011fi yeni tip koronavir\u00fcs (Kovid-19) a\u015f\u0131s\u0131n\u0131n, klinik deneylerde vir\u00fcse kar\u015f\u0131 g\u00fc\u00e7l\u00fc ba\u011f\u0131\u015f\u0131kl\u0131k …<\/p>\n","protected":false},"author":1,"featured_media":8393,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[46,367,196],"class_list":["post-8392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ekonomi","tag-abd","tag-asama","tag-asi"],"yoast_head":"\n